Image_5_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.TIF by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

Data_Sheet_1_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.docx by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

Image_6_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.TIF by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

Image_4_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.TIF by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

Image_1_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.TIF by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

Image_3_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.TIF by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

Image_2_Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level.TIF by Cheng Ding (34937)

“…</p>Results<p>The incidence and mortality decreased in most of the HBCs. The AAPCs of incidence ranged between −4.0 (Indonesia) and −0.2% (DR Congo) (all p < 0.05). …”

HLA high-resolution typing by next-generation sequencing in Pandemrix-induced narcolepsy by Alexander Lind (5221088)

“…Indeed, this extended haplotype was found in 30/31 patients (96.8%) and 178/636 GP (28.0%). In total, 15 alleles, four extended haplotypes, and six genotypes were found to be increased or decreased in frequency among NT1 patients compared to GP. …”

Datasheet3_Catheter ablation vs. drug therapy in the treatment of atrial fibrillation patients with heart failure: An update meta-analysis for randomized controlled trials.docx by Chun Lin (680865)

“…According to the meta-analysis, catheter ablation significantly reduced all-cause mortality compared with drug therapy [9.2% vs. 14.1%, OR: 0.62, (95% CI: 0.47–0.82), P = 0.0007, I²= 0%], improved LVEF [MD: 5.65%, (95% CI: 3.32–7.98), P < 0.00001, I²= 86%], reduced AF recurrence [41.6% vs. 61.9%, OR: 0.23, (95% CI: 0.11–0.48), P < 0.0001, I²= 82%], decreased the MLHFQ score [MD: −6.38, (95% CI: −11.09 to −1.67), P = 0.008, I²= 64%] and increased 6MWD [MD: 17.55, (95% CI: 15.77–19.33), P < 0.0001, I²= 37%]. …”

Table1_Catheter ablation vs. drug therapy in the treatment of atrial fibrillation patients with heart failure: An update meta-analysis for randomized controlled trials.docx by Chun Lin (680865)

“…According to the meta-analysis, catheter ablation significantly reduced all-cause mortality compared with drug therapy [9.2% vs. 14.1%, OR: 0.62, (95% CI: 0.47–0.82), P = 0.0007, I²= 0%], improved LVEF [MD: 5.65%, (95% CI: 3.32–7.98), P < 0.00001, I²= 86%], reduced AF recurrence [41.6% vs. 61.9%, OR: 0.23, (95% CI: 0.11–0.48), P < 0.0001, I²= 82%], decreased the MLHFQ score [MD: −6.38, (95% CI: −11.09 to −1.67), P = 0.008, I²= 64%] and increased 6MWD [MD: 17.55, (95% CI: 15.77–19.33), P < 0.0001, I²= 37%]. …”

Datasheet2_Catheter ablation vs. drug therapy in the treatment of atrial fibrillation patients with heart failure: An update meta-analysis for randomized controlled trials.docx by Chun Lin (680865)

“…According to the meta-analysis, catheter ablation significantly reduced all-cause mortality compared with drug therapy [9.2% vs. 14.1%, OR: 0.62, (95% CI: 0.47–0.82), P = 0.0007, I²= 0%], improved LVEF [MD: 5.65%, (95% CI: 3.32–7.98), P < 0.00001, I²= 86%], reduced AF recurrence [41.6% vs. 61.9%, OR: 0.23, (95% CI: 0.11–0.48), P < 0.0001, I²= 82%], decreased the MLHFQ score [MD: −6.38, (95% CI: −11.09 to −1.67), P = 0.008, I²= 64%] and increased 6MWD [MD: 17.55, (95% CI: 15.77–19.33), P < 0.0001, I²= 37%]. …”

Datasheet4_Catheter ablation vs. drug therapy in the treatment of atrial fibrillation patients with heart failure: An update meta-analysis for randomized controlled trials.docx by Chun Lin (680865)

“…According to the meta-analysis, catheter ablation significantly reduced all-cause mortality compared with drug therapy [9.2% vs. 14.1%, OR: 0.62, (95% CI: 0.47–0.82), P = 0.0007, I²= 0%], improved LVEF [MD: 5.65%, (95% CI: 3.32–7.98), P < 0.00001, I²= 86%], reduced AF recurrence [41.6% vs. 61.9%, OR: 0.23, (95% CI: 0.11–0.48), P < 0.0001, I²= 82%], decreased the MLHFQ score [MD: −6.38, (95% CI: −11.09 to −1.67), P = 0.008, I²= 64%] and increased 6MWD [MD: 17.55, (95% CI: 15.77–19.33), P < 0.0001, I²= 37%]. …”

Datasheet1_Catheter ablation vs. drug therapy in the treatment of atrial fibrillation patients with heart failure: An update meta-analysis for randomized controlled trials.docx by Chun Lin (680865)

“…According to the meta-analysis, catheter ablation significantly reduced all-cause mortality compared with drug therapy [9.2% vs. 14.1%, OR: 0.62, (95% CI: 0.47–0.82), P = 0.0007, I²= 0%], improved LVEF [MD: 5.65%, (95% CI: 3.32–7.98), P < 0.00001, I²= 86%], reduced AF recurrence [41.6% vs. 61.9%, OR: 0.23, (95% CI: 0.11–0.48), P < 0.0001, I²= 82%], decreased the MLHFQ score [MD: −6.38, (95% CI: −11.09 to −1.67), P = 0.008, I²= 64%] and increased 6MWD [MD: 17.55, (95% CI: 15.77–19.33), P < 0.0001, I²= 37%]. …”

Dataset: Increased Organic Carbon Burial in Northern Florida Mangrove-Salt Marsh Transition Zones by Derrick Vaughn (7900301)

“…Higher amino acid concentrations in mangrove soils relative to mangrove biomass (1.8-2.3 mmol gC^-1 vs. 0.2-0.9 mmol gC^-1) and lower C/N indicated these mangrove sites receive higher algal inputs than the transition and salt marsh sites, attributed to greater tidal inundation in the mangrove sites given their position near the shoreline. …”

Dataset used in the manuscript. by Saeun Park (20410160)

“…Caregivers had more severe symptoms of depression and/or anxiety if they experienced greater changes in living situations or decreases in physical activity (CESD-20: β = 3.35, 95% CI [1.00, 5.70], p = .01), food insecurity (HSCL-25: β = 3.25, 95% CI [0.41, 6.10], p = .03, CESD-25: β = 3.09, 95% CI [0.79, 5.39], p = .01), and domestic violence (HSCL-25: β = 3.82, 95% CI [0.94, 6.70], p = .01) during COVID-19. …”

Data_Sheet_1_Deciphering the mechanism of jujube vinegar on hyperlipoidemia through gut microbiome based on 16S rRNA, BugBase analysis, and the stamp analysis of KEEG.zip by Guofeng Duan (15650228)

Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease by Hsiao-Han Wang (429124)

“…</p><p>Results</p><p>The mean age was 62.4 years, mean sK level was 4.2±0.5 mEq/L and average eGFR was 40.6 ml/min per 1.73 m². …”

Harmonic Shears for Skeletonized Internal Thoracic Arteries and Great Saphenous Vein Harvesting by Corrado Cavozza (5496989)

“…<i><a href="https://doi.org/10.1016/j.athoracsur.2009.09.061">Ann Thorac Surg. 2010;89(2):403-408</a></i>.…”